Atlas Trials

CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma

Clinical trial NCT04381741 · UNKNOWN

Trial details

NCT number
NCT04381741
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Diffuse Large B-cell Lymphoma
Start date
2020-06-18
Primary completion
2023-09-01
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.